CA2944211C - Compositions and methods for treating neurodegenerative diseases - Google Patents

Compositions and methods for treating neurodegenerative diseases Download PDF

Info

Publication number
CA2944211C
CA2944211C CA2944211A CA2944211A CA2944211C CA 2944211 C CA2944211 C CA 2944211C CA 2944211 A CA2944211 A CA 2944211A CA 2944211 A CA2944211 A CA 2944211A CA 2944211 C CA2944211 C CA 2944211C
Authority
CA
Canada
Prior art keywords
optionally substituted
alkyl
hydrogen
antagonist
amide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2944211A
Other languages
English (en)
French (fr)
Other versions
CA2944211A1 (en
Inventor
Michael J. Brownstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Azevan Pharmaceuticals Inc
Original Assignee
Azevan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azevan Pharmaceuticals Inc filed Critical Azevan Pharmaceuticals Inc
Publication of CA2944211A1 publication Critical patent/CA2944211A1/en
Application granted granted Critical
Publication of CA2944211C publication Critical patent/CA2944211C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2944211A 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases Active CA2944211C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461971862P 2014-03-28 2014-03-28
US61/971,862 2014-03-28
PCT/US2015/023060 WO2015148962A1 (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CA2944211A1 CA2944211A1 (en) 2015-10-01
CA2944211C true CA2944211C (en) 2022-10-04

Family

ID=54196457

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2944211A Active CA2944211C (en) 2014-03-28 2015-03-27 Compositions and methods for treating neurodegenerative diseases

Country Status (22)

Country Link
US (4) US9802925B2 (enExample)
EP (1) EP3122743B1 (enExample)
JP (2) JP7255967B2 (enExample)
KR (2) KR20160130853A (enExample)
CN (3) CN116327950A (enExample)
AU (2) AU2015237253B2 (enExample)
BR (1) BR112016022575A2 (enExample)
CA (1) CA2944211C (enExample)
DK (1) DK3122743T3 (enExample)
ES (1) ES2939959T3 (enExample)
FI (1) FI3122743T3 (enExample)
IL (1) IL248074B (enExample)
MX (2) MX382453B (enExample)
MY (1) MY184878A (enExample)
NZ (1) NZ724718A (enExample)
PL (1) PL3122743T3 (enExample)
RU (1) RU2742773C2 (enExample)
SG (2) SG10202001065SA (enExample)
SI (1) SI3122743T1 (enExample)
TW (2) TWI839623B (enExample)
WO (1) WO2015148962A1 (enExample)
ZA (1) ZA201606673B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
DK3122743T3 (da) 2014-03-28 2023-02-20 Azevan Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
TWI622380B (zh) * 2017-01-17 2018-05-01 正崴精密工業股份有限公司 生理訊號測量裝置及其血氧濃度演算方法
JP2020534274A (ja) * 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法
KR20230124992A (ko) * 2020-12-23 2023-08-28 셀진 코포레이션 신경변성 질환의 치료를 위한 카르복실산 함유 인다닐화합물
WO2023164710A1 (en) * 2022-02-28 2023-08-31 The Trustees Of Columbia University In The City Of New York Avpr1a blockade to reduce social isolation-induced anxiety in females

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4314081A (en) 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
NL7503310A (nl) 1975-03-20 1976-09-22 Philips Nv Verbindingen met antidepressieve werking.
US4576753A (en) 1975-10-06 1986-03-18 Fujisawa Pharmaceutical Co., Ltd. Azetidinone compounds and processes for preparation thereof
GB1526331A (en) 1976-01-14 1978-09-27 Kefalas As Phthalanes
US4341698A (en) 1979-06-21 1982-07-27 Richardson-Merrell Inc. Enkaphalin derivatives
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
JPS56125361A (en) 1980-03-07 1981-10-01 Sagami Chem Res Center Azetidinone compound
JPS6033439B2 (ja) 1980-03-07 1985-08-02 財団法人相模中央化学研究所 ジペプチドの製造方法
FR2508035A1 (fr) 1981-06-23 1982-12-24 Fabre Sa Pierre Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central
US4761501A (en) 1983-10-26 1988-08-02 American Home Products Corporation Substituted phenylacetamides
US4751299A (en) 1983-11-18 1988-06-14 Takeda Chemical Industries, Ltd. Optically active β-lactams and method of their production
US4665171A (en) 1985-07-17 1987-05-12 Harvard University Process and intermediates for β-lactam antibiotics
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4734498A (en) 1986-07-10 1988-03-29 Eli Lilly And Company 3β-succinimidoazetidinones as chiral intermediates
US4772694A (en) 1986-07-24 1988-09-20 Eli Lilly And Company Chiral 3-(1,2,5-trisubstituted imidazolidinone) azetidinone antibiotic intermediates
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
US5627165A (en) 1990-06-13 1997-05-06 Drug Innovation & Design, Inc. Phosphorous prodrugs and therapeutic delivery systems using same
WO1992005784A1 (en) 1990-10-02 1992-04-16 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
GB9204001D0 (en) 1992-02-25 1992-04-08 Jacobs Suchard Ag Process for producing reduced fat nuts
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
WO1994001402A1 (en) 1992-07-13 1994-01-20 Merck Sharp & Dohme Limited Heterocyclic amide derivatives as tachykinin derivatives
JP3507494B2 (ja) 1992-08-13 2004-03-15 ワーナー−ランバート・コンパニー タキキニン拮抗薬
FR2696178B1 (fr) 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
NZ267209A (en) 1993-05-06 1997-09-22 Merrell Dow Pharma Substituted pyrrolidin-3-yl-alkyl-piperidine derivatives, preparation and pharmaceutical compositions thereof
US5512563A (en) 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5759865A (en) 1995-05-03 1998-06-02 Eli Lilly And Company Combinatorial process for synthesizing azetidinone analogs
GB9511694D0 (en) 1995-06-09 1995-08-02 Fujisawa Pharmaceutical Co Benzamide derivatives
CA2246753C (en) 1996-02-23 2005-05-10 Eli Lilly And Company Non-peptidyl vasopressin v1a antagonists
HUP0002480A3 (en) 1997-07-30 2002-09-30 Wyeth Corp Pyrrolo[2,1-c][1,4]benzodiazepine derivatives, their use, process for their preparation and pharmaceutical compositions containing them
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
KR100517644B1 (ko) 1997-10-27 2005-09-28 닥터 레디스 레보러터리즈 리미티드 신규의 삼원 화합물 및 그 약학적 용도, 그 제조방법 및이들을 포함하는 약제학적 조성물
WO2001012184A1 (en) 1999-08-16 2001-02-22 Revaax Pharmaceuticals, Llc Neurotherapeutic composition and method
GB0019006D0 (en) 2000-08-04 2000-09-20 Astrazeneca Ab Novel compounds
CA2462903C (en) * 2001-10-12 2011-09-20 Serenix Pharmaceuticals, Llc Beta-lactamyl vasopressin v1a antagonists
US7179907B2 (en) 2001-12-18 2007-02-20 Bruce Eaton Antibiotic compounds
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
GB0224919D0 (en) 2002-10-25 2002-12-04 Pfizer Ltd Triazole compounds useful in therapy
WO2005007658A2 (en) 2003-07-14 2005-01-27 Arena Pharmaceuticals, Inc. Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
US20060281728A1 (en) 2003-10-03 2006-12-14 Guillon Christophe D 3-Substituted beta-lactamyl vasopressin v1a antagonists
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
EP1632494A1 (en) 2004-08-24 2006-03-08 Ferring B.V. Vasopressin v1a antagonists
EP1669776A1 (de) 2004-12-11 2006-06-14 Leica Geosystems AG Handhaltbares Vermessungsgerät und Vermessungsverfahren für ein solches Vermessungsgerät
FR2881744B1 (fr) 2005-02-09 2007-04-27 Sanofi Aventis Sa Derives de n-[(4,5-diphenyl-2-thienyl)methyl]amine, leur preparation et leur application en therapeutique
EP1868434A4 (en) 2005-03-22 2011-10-26 Azevan Pharmaceuticals Inc BETA-LACTAMYL ALKANIC ACIDS FOR THE TREATMENT OF PREMIERSTRUELLEN FAULTS
JP2008540633A (ja) 2005-05-18 2008-11-20 ファイザー・リミテッド バソプレッシン拮抗薬としての１，２，４−トリアゾール誘導体
ES2726942T3 (es) 2005-07-19 2019-10-10 Azevan Pharmaceuticals Inc Antagonista de vasopresina de tipo beta-lactamil fenilalanina, cisteína y serina
WO2007109615A2 (en) 2006-03-21 2007-09-27 Azevan Pharmaceuticals, Inc. β -LACTAMYL VASOPRESSIN V2 ANTAGONISTS
WO2008034032A2 (en) 2006-09-14 2008-03-20 Azevan Pharmaceuticals, Inc. Beta-lactam cannabinoid receptor modulators
JP2010504352A (ja) 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
JP5450108B2 (ja) 2007-03-23 2014-03-26 アレイ バイオファーマ、インコーポレイテッド グルコキナーゼ活性化剤としての２−アミノピリジン類似体
US20090182011A1 (en) * 2008-01-16 2009-07-16 University Of Illinois Chicago Chimeric Nitrate Esters and Use of the Same in a Treatment for Depression
FR2927625B1 (fr) 2008-02-19 2010-03-12 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique
FR2930249B1 (fr) 2008-04-21 2010-05-14 Sanofi Aventis Nouveaux derives de 3-aminoalkyl-1,3-dihydro-2h-indol-2-one, leur preparation et leur application en therapeutique.
CA2804001C (en) 2010-07-01 2021-02-09 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
CA2901577A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
DK3122743T3 (da) 2014-03-28 2023-02-20 Azevan Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme
JP2020534274A (ja) 2017-09-15 2020-11-26 アゼヴァン ファーマシューティカルズ，インコーポレイテッド 脳損傷を治療するための組成物及び方法

Also Published As

Publication number Publication date
IL248074A0 (en) 2016-11-30
TWI736519B (zh) 2021-08-21
SI3122743T1 (sl) 2023-07-31
RU2742773C2 (ru) 2021-02-10
US11319306B2 (en) 2022-05-03
US20200102294A1 (en) 2020-04-02
JP2022116001A (ja) 2022-08-09
CN106459021A (zh) 2017-02-22
BR112016022575A2 (pt) 2017-08-15
FI3122743T3 (fi) 2023-03-02
CN116139282A (zh) 2023-05-23
US20180201608A1 (en) 2018-07-19
DK3122743T3 (da) 2023-02-20
IL248074B (en) 2020-07-30
AU2019253831B2 (en) 2021-10-28
CA2944211A1 (en) 2015-10-01
EP3122743B1 (en) 2022-11-09
TW202216702A (zh) 2022-05-01
US10364236B2 (en) 2019-07-30
AU2015237253A1 (en) 2016-10-20
ES2939959T3 (es) 2023-04-28
EP3122743A4 (en) 2017-11-29
CN116327950A (zh) 2023-06-27
US20230123729A1 (en) 2023-04-20
JP7255967B2 (ja) 2023-04-11
MY184878A (en) 2021-04-29
SG11201608064WA (en) 2016-10-28
CN106459021B (zh) 2023-04-07
US20170174670A1 (en) 2017-06-22
RU2016138349A3 (enExample) 2018-10-26
MX2021005502A (es) 2023-01-16
ZA201606673B (en) 2019-06-26
TWI839623B (zh) 2024-04-21
AU2015237253B2 (en) 2019-11-14
NZ724718A (en) 2023-04-28
US9802925B2 (en) 2017-10-31
KR20160130853A (ko) 2016-11-14
KR20220151037A (ko) 2022-11-11
AU2019253831A1 (en) 2019-11-14
WO2015148962A1 (en) 2015-10-01
SG10202001065SA (en) 2020-04-29
JP2017510645A (ja) 2017-04-13
TW201620902A (zh) 2016-06-16
MX2016012645A (es) 2017-01-11
PL3122743T3 (pl) 2023-05-02
KR102725123B1 (ko) 2024-11-04
MX382453B (es) 2025-03-13
EP3122743A1 (en) 2017-02-01
RU2016138349A (ru) 2018-05-04

Similar Documents

Publication Publication Date Title
AU2019253831B2 (en) Compositions and methods for treating neurodegenerative diseases
AU2018333051A1 (en) Compositions and methods for treating brain injury
US10953001B2 (en) Methods for treating post traumatic stress disorder
HK1234030A1 (en) Compositions and methods for treating neurodegenerative diseases
HK1234030B (en) Compositions and methods for treating neurodegenerative diseases
HK1258668B (en) Compounds for use in the treatment of intermittent explosive disorder
HK1184640B (en) Methods for treating post traumatic stress disorder
HK1184640A (en) Methods for treating post traumatic stress disorder
HK1233638B (en) Compositions and methods for treating neurodegenerative diseases

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200327

EEER Examination request

Effective date: 20200327